Long‐term edaravone efficacy in amyotrophic lateral sclerosis: Post‐hoc analyses of Study 19 (MCI186‐19)-Reference-Cited by-同舟云学术

Long‐term edaravone efficacy in amyotrophic lateral sclerosis: Post‐hoc analyses of Study 19 (MCI186‐19)

Author:

Shefner Jeremy¹,Heiman‐Patterson Terry²,Pioro Erik P.³,Wiedau‐Pazos Martina⁴,Liu Shawn⁵,Zhang Jeffrey⁶,Agnese Wendy⁷,Apple Stephen⁸

Affiliation:

1. Barrow Neurological Institute Phoenix Arizona

2. Temple University Philadelphia Pennsylvania

3. Cleveland Clinic Cleveland Ohio

4. David Geffen School of MedicineUniversity of California, Los Angeles Los Angeles California

5. Mitsubishi Tanabe Pharma Development America, Inc. Jersey City New Jersey

6. Princeton PharmatechPrinceton Junction New Jersey

7. Formerly Mitsubishi Tanabe Pharma America, Inc. Jersey City New Jersey

8. Mitsubishi Tanabe Pharma America, Inc. Jersey City New Jersey

Funder

Mitsubishi Tanabe Pharma

Publisher

Wiley

Subject

Physiology (medical),Cellular and Molecular Neuroscience,Clinical Neurology,Physiology

Link

Reference15 articles.

4. Radicava® (edaravone injection) [package insert]. Jersey City NJ: Mitsubishi Tanabe Pharma Corporation; August 2017.

5. Rilutek® (riluzole) [package insert]. Bridgewater NJ: sanofi‐aventis U.S. LLC; November 2012.

Cited by 52 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献